leisure time -WSS

leisure time

author：hotspot 2025-10-02 18:31:42 - browse：9

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Feng Zhang, Grail founder join forces on new gene editing startup

WSS

Wellcome Trust names Røttingen as its new CEO

How doctors and nurses shape Google's AI

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Antibiotic resistance and the global rise in human conflict

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

hotspot

leisure time

explore

As demand for Covid shots wanes, Moderna seeks its next success

Nick Jonas talks about managing diabetes along with his career

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Peter Marks talks Operation Warp Speed for Rare Diseases

State Dept. review finds Biden bears some blame for Afghanistan failures

How clinical AI models' predictive power can degrade over time

In age of alternative facts, a scholarly course on calling out crap

Akero's treatment for NASH falls short in cirrhosis study

Continuity nursing helped my family in our darkest PICU moments

Better Therapeutics data on benefit with GLP

hotspot

What's changing in Medicare's open enrollment this year?

Morgan Health, with ambitious aims, wants you to know it’s still here

JPM: CVS says Medicare Advantage patients are impacting profits

European regulators consider appeal over Amylyx ALS drug

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Eight reasons why you should get an updated Covid vaccine

hotspot

focus

entertainment

entertainment